Opus Genetics (IRD) Return on Equity (2011 - 2026)

Opus Genetics (IRD) has 16 years of Return on Equity data on file, last reported at 0.07% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.07%, up 17.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.07% (up 17.0% YoY), and the FY2025 annual result was 0.04%, down 2.0% from the prior year.
• Return on Equity improved to 0.07% in Q1 2026 per IRD's latest filing, from 0.05% in the prior quarter.
• Over five years, Return on Equity peaked at 0.07% in Q1 2026 and troughed at 0.1% in Q1 2025.
• A 5-year average of 0.01% and a median of 0.01% in 2024 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2022 and 2026: Return on Equity sank 34 bps in 2022, then grew 17 bps in 2026.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then slumped by 132 bps to 0.0% in 2023, then slumped by 1307 bps to 0.03% in 2024, then plunged by 66 bps to 0.05% in 2025, then surged by 251 bps to 0.07% in 2026.
• Business Quant data shows IRD's Return on Equity at 0.07% in Q1 2026, 0.05% in Q4 2025, and 0.06% in Q3 2025.